Sandler Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Sandler Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-69,300	Closed	-$7.47M	–	92
2020 Q1	$7.47M	Buy	+69,300	New	+$7.98M	1.03%	40
2015 Q2	–	Sell	-96,000	Closed	-$11M	–	202
2015 Q1	$11M	Buy	+96,000	New	+$10.6M	0.68%	42
2014 Q4	–	Sell	-234,000	Closed	-$21.3M	–	224
2014 Q3	$21.3M	Buy	+234,000	New	+$20.5M	1.01%	25

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Sandler Capital Management's IBB Position: Q2 2020 in Review

Sandler Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2020, closing a stake of 69,300 shares — an estimated $7.47M sold.

Sandler Capital Management first reported a position in IBB in Q3 2014 and held it in 3 quarters. The position peaked at $21.3M in Q3 2014. 766 funds tracked by Wall St. Rank hold IBB as of Q2 2020.

Sandler Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2020 after selling out during the quarter.
Sandler Capital Management sold 69,300 iShares Biotechnology ETF shares in Q2 2020, an estimated $7.47M.
Sandler Capital Management first reported a position in iShares Biotechnology ETF in Q3 2014 and held it in 3 quarters.
Sandler Capital Management's iShares Biotechnology ETF position peaked at $21.3M in Q3 2014.
766 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2020.

Based on Sandler Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.